Le Lézard
Classified in: Health
Subject: SVY

The osteotomy plates market will register a CAGR of close to 5% by 2022


LONDON, Jan. 17, 2019 /PRNewswire/ -- About this market
Product bundling to gain traction in the market. The global osteotomy plates market is witnessing product bundling strategies by market players. Many companies are implementing product bundling strategies and offering a combination of two or more products or services. Technavio's analysts have predicted that the osteotomy plates market will register a CAGR of close to 5% by 2022.

Download the full report: https://www.reportbuyer.com/product/5713254

Market Overview
Increasing prevalence of bone-related disorders
There is an increase in the prevalence of bone-related disorders such as osteoarthritis and osteoporosis. Osteoporosis is one of the common causes of fractures.
Complications associated with osteotomy procedures
Osteotomy surgeries involve potential risks such as nerve damage, bleeding, blood clots, infections, lack of full range motion, scar formation, development of arthritis, and reinjuries to the soft tissue or joint.
For the detailed list of factors that will drive and challenge the growth of the osteotomy plates market during the 2018-2022, view our report.

Competitive Landscape
The market appears to be fragmented and with the presence of several companies including Arthrex and B. Braun Melsungen the competitive environment is quite intense. Factors such as the increase in the prevalence of bone-related disorders and the product bundling, will provide considerable growth opportunities to osteotomy plates manufactures. Arthrex, B. Braun Melsungen, Johnson & Johnson, Smith & Nephew, Stryker, Wright Medical Group, and Zimmer Biomet are some of the major companies covered in this report.

Download the full report: https://www.reportbuyer.com/product/5713254

About Reportbuyer
Reportbuyer is a leading industry intelligence solution that provides all market research reports from top publishers

For more information:
Sarah Smith
Research Advisor at Reportbuyer.com
Email: [email protected]
Tel: +1 (718) 213 4904
Website: www.reportbuyer.com

SOURCE ReportBuyer


These press releases may also interest you

18 avr 2024
The 31st Canadian Cancer Society (CCS) Daffodil Ball, which took place this evening at Windsor Station in Montreal, raised $1,474,785 to fund innovative research projects and essential support programs for people living with cancer. The largest...

18 avr 2024
The report titled "Clinical Trials Matching Software Market by Functionality (Analytics & Reporting, Compliance Tracking, Data Management), Deployment (Cloud & Web Based, On-Premise), End-Use - Global Forecast 2024-2030" is now available on...

18 avr 2024
South Korea's biotechnology company Hyundai Bioscience (CEO Oh Sang-gi, www.hyundaibioscience.com) announced on April 15 that it would carry out global clinical tests aimed at treating all serotypes of Dengue virus infection....

18 avr 2024
The report titled "Progressive Familial Intrahepatic Cholestasis Treatment Market by Drug Type (Cholestyramine, Rifampicin, Ursodeoxycholic Acid), Distribution Channel (Hospital Pharmacies, Online Pharmacies, Retail Pharmacies), End-Users - Global...

18 avr 2024
RevolKa Ltd. (Norio Hamamatsu, President & CEO), a venture-backed biotech company providing a game-changing protein engineering technology platform and La Jolla Institute for Immunology (LJI) (Erica Saphire, President & CEO) agreed to start a...

18 avr 2024
Takeda (TSE:4502/NYSE:TAK) today announced that the U.S. Food and Drug Administration (FDA) has approved ENTYVIO® (vedolizumab) subcutaneous (SC) administration for maintenance therapy in adults with moderately to severely active Crohn's disease (CD)...



News published on and distributed by: